Mike Sharma, MD, MSc

Mike Sharma, MD, discusses early efficacy signals, long-term stroke risk, patient impact, and why antithrombotic treatment should be tailored to each condition.

Mike Sharma, MD, discusses the asundexian trial’s broad patient population, results across stroke subtypes, and bleeding outcomes.